Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ⅱ Trial of Neoadjuvant Chemotherapy Combined With Camrelizumab Followed by Chemoradiotherapy in Patients Without Distant Metastasis Nasopharyngeal Carcinoma

NCT04782765 is registered in ClinicalTrials.gov with Tianjin Medical University Cancer Institute and Hospital as lead sponsor.

NCT NCT04782765
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04782765 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ⅱ Trial of Neoadjuvant Chemotherapy Combined With Camrelizumab Followed by Chemoradiotherapy in Patients Without Distant Metastasis Nasopharyngeal Carcinoma
Lead sponsor
Tianjin Medical University Cancer Institute and Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
March 20, 2021
Completion date
March 20, 2025
Enrollment
59 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

disease-free survival rate